Thomas Elter

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2011 · 372 citations

Medicine, Oncology, Pharmacotherapy +14

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt et al. · Blood · 2014 · 276 citations

Medicine, Hematology, Oncology +12

Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Thomas Elter, Peter Borchmann, H. Schulz et al. · Journal of Clinical Oncology · 2005 · 212 citations

Medicine, Oncology, Pharmacotherapy +17

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

H. Schulz, U. Rehwald, Franck Morschhauser et al. · Blood · 2007 · 181 citations · Full text

Medicine, Immunology, Oncology +15

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

Agnieszka Korfel, Thomas Elter, E. Thiel et al. · Haematologica · 2012 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +15